NANOG® is indicated for the treatment of gastrointestinal meteorism (accumulation of gas in the stomach and intestines) and aerophagia (swallowing of air that accumulates in the stomach) in infants and children.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

The recommended dose for infants and children is 20 drops (0.6 mL), 2 to 4 times daily, unless otherwise directed by a physician, preferably after meals.
Shake well before use.
The drops may be mixed with a small amount of water.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

NANOG® is not contraindicated in individuals with coeliac disease (a condition affecting the small intestine).
Do not use NANOG® if you are allergic to simeticone or any of the other ingredients of this medicine.
NANOG® should not be administered to children under 28 days of age.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

Talk to your doctor or pharmacist before using NANOG®.
Do not exceed the recommended dose.
You should seek medical advice if satisfactory results are not achieved after a short treatment period (7 days).

If symptoms persist or worsen, consult your doctor.
Particularly when this medicine is used in children, medical advice should be sought.

NANOG® with food and drink: No interactions with food or beverages are known or have been reported.
There are insufficient data on the use of NANOG® in pregnant women. Therefore, it should not be used during pregnancy unless clearly necessary and only after the physician has assessed the benefit–risk balance.
It is not known whether simeticone is excreted in human breast milk. The excretion of simeticone in breast milk has not been studied in animals. The decision whether to continue or discontinue breastfeeding or to continue or discontinue treatment with simeticone should consider the benefits of breastfeeding for the child and the benefits of simeticone treatment for the woman.
No effects on the ability to drive or operate machinery have been observed with the use of NANOG®.
This emulsion contains parabens (used as preservatives), which may cause allergic reactions, including delayed allergic reactions.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
No drug interactions are known or have been reported.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

Like all medicines, NANOG® can cause side effects, although not everybody gets them.
No clinically significant side effects are known. It is important to follow the instructions provided in this leaflet, as this may reduce the risk of side effects.
If you experience any side effects, including any possible side effects not listed in this leaflet, talk to your doctor or pharmacist.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020